Afatinib (BIBW 2992) is an orally active, irreversible EGFR and HER2 inhibitor (IC50s: 0.5 nM, 14 nM). It enhances adriamycin cytotoxicity in resistant lung cancer cells and reduces tumor growth in gastric cancer models. Used in NSCLC research. Reagent grade, for research use only.
Usually ships within 24 hours.